Starpharma Holdings Limited (SPHRF)
OTCMKTS · Delayed Price · Currency is USD
0.2128
0.00 (0.00%)
At close: Nov 4, 2025
Starpharma Holdings Revenue
In the fiscal year ending June 30, 2025, Starpharma Holdings had annual revenue of 5.85M AUD, down -40.04%. Starpharma Holdings had revenue of 3.42M in the half year ending June 30, 2025, with 30.05% growth.
Revenue
5.85M AUD
Revenue Growth
-40.04%
P/S Ratio
31.73
Revenue / Employee
146.25K AUD
Employees
40
Market Cap
121.71M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 5.85M | -3.91M | -40.04% |
| Jun 30, 2024 | 9.76M | 5.41M | 124.64% |
| Jun 30, 2023 | 4.34M | -819.00K | -15.87% |
| Jun 30, 2022 | 5.16M | 1.68M | 48.04% |
| Jun 30, 2021 | 3.49M | -3.63M | -50.99% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 260.43M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Mid-Atlantic Home Health Network | 27.00M |
| Silence Therapeutics | 25.83M |
| Nuo Therapeutics | 2.61M |
Starpharma Holdings News
- 7 weeks ago - ASX 200 LIVE: ASX climbs, tracking Wall Street; Starpharma inks deal with Roche Group; Reece plans share buyback; Santos receives first gas in Barossa field. - The Australian Financial Review
- 2 years ago - Starpharma: Patience Needed, But A Lot To Like - Seeking Alpha
- 3 years ago - Starpharma presents compelling data in Prostate Cancer at ESMO - PRNewsWire
- 3 years ago - Starpharma signs new DEP® agreement with MSD - PRNewsWire
- 4 years ago - Starpharma releases positive DEP® phase 2 interim results in prostate cancer - PRNewsWire
- 4 years ago - US Patent and Trademark Office grants new patent for DEP® cabazitaxel, one of Starpharma's phase 2 clinical-stage cancer treatments - PRNewsWire
- 4 years ago - Stopping Infection: A Missing Link In The Delta Puzzle? Unloved Investment Opportunity In Starpharma - Seeking Alpha
- 4 years ago - Early-Stage Covid Treatment Prospects: Merck/Ridgeback Bio And Starpharma Lead The Pack - Seeking Alpha